Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lasa SupergenericsNSE:LASA 45 Earnings per Share (Diluted) is ₹-0.80 as of Jun. 2026. GuruFocus rates NSE:LASA with a GF Score™ of 45/100 and a GF Value™ of ₹1.18 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 783 Drug Manufacturers companies, Lasa Supergenerics ranks better than 58.49% on this metric.
Lasa Supergenerics's EPS (Basic) for the
three
months ended in Jun. 2026 was ₹-0.71.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-0.80.
During the past 3 years, the average EPS without NRIGrowth Rate was 14.10% per year.
During the past 11 years, Lasa Supergenerics's highest 3-Year average EPS without NRI Growth Rate was 14.10% per year. The lowest was -48.20% per year. And the median was 1.10% per year.
Lasa Supergenerics (NSE:LASA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Lasa Supergenerics Earnings per Share (Diluted) Related Terms
Lasa Supergenerics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Lasa Supergenerics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lasa Supergenerics Earnings per Share (Diluted) Chart
NSE:LASA vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lasa Supergenerics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lasa Supergenerics PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lasa Supergenerics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Lasa Supergenerics's PE Ratio falls into.
Lasa Supergenerics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Lasa Supergenerics's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of ₹-0.80 mean?
Lasa Supergenerics (NSE:LASA) has a Earnings per Share (Diluted) of ₹-0.80 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Lasa Supergenerics and its competitors. According to the industry distribution chart, Lasa Supergenerics ranks #325 out of 783 companies in the Drug Manufacturers industry, placing it in the top 41.5%.
Is Lasa Supergenerics' Earnings per Share (Diluted) too high?
Lasa Supergenerics' current Earnings per Share (Diluted) is ₹-0.80. Based on the distribution chart, Lasa Supergenerics ranks #325 out of 783 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lasa Supergenerics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lasa Supergenerics' Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lasa Supergenerics ranks #325 out of 783 companies for Earnings per Share (Diluted). This puts Lasa Supergenerics in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.80, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Lasa Supergenerics and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lasa Supergenerics's current Earnings per Share (Diluted) is ₹-0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lasa Supergenerics stock overvalued right now?
Based on GuruFocus' analysis, Lasa Supergenerics (NSE:LASA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1.18, compared to a current price of ₹6.52 — trading 452.5% above its estimated fair value. The current Earnings per Share (Diluted) is ₹-0.80. Lasa Supergenerics' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Lasa Supergenerics (NSE:LASA), the current Earnings per Share (Diluted) is ₹-0.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lasa Supergenerics (NSE:LASA) Overvalued in 2026?
Based on GuruFocus' analysis, Lasa Supergenerics stock appears to be overvalued.
The current stock price of ₹6.52 is trading 452.5% above its estimated GF Value™ of ₹1.18.
GuruFocus considers Lasa Supergenerics to be Significantly Overvalued.
Key valuation signals for NSE:LASA:
Earnings per Share (Diluted): ₹-0.80
GF Value™: ₹1.18 vs. price of ₹6.52 (452.5% above fair value)
No single metric tells the full story. See the NSE:LASA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lasa Supergenerics Ltd is engaged in the research, manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and related products. The company specializes in catalyst chemistry and manufactures anthelmintic and veterinary API products. Its product range includes API products, other API products, animal feed ingredients, and reagents for therapeutic use.
45GF Score
Get the complete analysis for NSE:LASA
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LASA has been successfully added to your 
